AI
Saturday, December 26, 2015 6:53:32 PM
Bruce Freimark (Dir/PreClin-Oncology) speaking 1-26-16 at GTCbio's Novel-Immunotherapeutics-Summit, SanDiego
Jan25-26 2016: “GTCbio's Novel Immunotherapeutics Summit”, San Diego
https://www.gtcbio.com/conferences/immunotherapeutics-summit-overview
GTC = Global Technology Community https://www.gtcbio.com/about-us
4 Sub-Conferences, including: 8TH IMMUNOTHERAPEUTICS & IMMUNOMONITORING
1-26-15: SESSION: ”Combinatorial Immunotherapies” - Moderator: Bruce Freimark, Peregrine Pharm.
4 Speakers:
*9:35am “DNA Vaccines with T-Cell Checkpoint Blockade”, Douglas McNeel, UNIV./WISCONSIN
*10:00am “Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Cells in the Tumor Microenvironment”, Bruce Freimark (Res.Dir./Preclin.Oncology), PEREGRINE PHARMACEUTICALS
Abstract: The underlying cause for the failure of immune checkpoint blockade is persistent, multifocal immune suppression in the tumor microenvironment. This is due to the absence of pre-existing antitumor Teff because of the action of immune checkpoints that induce immunosuppressive cytokines and recruit tumor infiltrating myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg), and M2 macrophages. Phosphatidylserine (PS) is segregated to the inner leaflet of the plasma membrane but becomes externalized to the outer leaflet in tumor cells where it contributes as an upstream checkpoint inhibitor to an immunosuppressive environment. Antibody blockade of PS reprograms the immune cells in the tumor microenvironment to support immune activation. Antibody-mediated PS blockade reduces the levels of MDSCs, TGF-beta, and IL-10 and increases the levels of TNF-alpha and IL-12. PS blockade also re-polarizes tumor-associated M2 macrophages to a M1 phenotype which promotes the maturation of dendritic cells and induces of adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies in models of melanoma and breast cancer and correlates with an increase in the infiltration of activated T cells and the induction of adaptive immunity. In summary, PS blockade in combination with targeted therapy and other immune checkpoint inhibitors promotes a localized, anti-tumor response and represents a promising strategy to enhance cancer immunotherapy.
*10:25am “Cancer Vaccines in the Era of Checkpoint Blockade”, Willem Overwijk, MD.ANDERSON
*11:20am “Myeloid-Derived IL-10 & PD-1 Create a Vicious Immune...”, Keith Knutson, MAYO CLINIC
= = = = = = = = = = =OTHER KNOWN UPCOMINGS (2016):
Jan26: “GTCbio's Novel Immunotherapeutics Summit”, San Diego http://tinyurl.com/z3dyful
...10am, Dr. Bruce Freimark(ResDir./Preclin.Oncology): “Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Cells in the Tumor Microenvironment”
Jan26-28/Avid/Booth20: CASSS' 20th Symposium on the Interface of Reg.&Anal. Sciences for Biotech Health Products, WashDC http://www.casss.org/?WCBP1600
Mar6-11: CHI’s 23rd Molecular Med TRI-CON 2016, SanFran http://www.triconference.com (Speaker: Dr. Jeff Hutchins, VP/Preclin.Res.)
~Mar10: FY'16Q3 (qe 1-31-16) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm
Mar14-17/Avid/Booth712: IBC's BioProcess Intl. West, Oakland http://www.ibclifesciences.com/BPIWest/overview.xml
Mar15-17: Immune Checkpoint Inhibitors Conf., Boston http://immune-checkpoint.com (Peregrine is 1 of 4 Corp. Sponsors; Speaker: Dr. Jeff Hutchins, VP/Preclin.Res.)
Jun6-9/Avid/Booth5562: BIO Intl. Convention, SanFran http://convention.bio.org
= = = = = = = = = =PREVIOUS BAVI MOA PRESENTATIONS:
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
BAVI MOA 8-26-15: Jeff Hutchins(VP/PreClin-Res) ImVacS’15 Talk – 29pg. Slideshow http://tinyurl.com/qz64pzg
…“Expansion & Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides): http://tinyurl.com/ooxkhq7
BAVI MOA 2-9-15: PPHM/ResDir. Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides: http://tinyurl.com/q6cx4w6
BAVI MOA 12-12-14 San Antomio Breast Cancer Symposium, Dr. Bruce Freimark, Bavi+anti-PD-1 vs. Breast Cancer http://tinyurl.com/p5ng6vs
BAVI MOA 11-2014 SITC’14: 3 posters on preclin. Bavi+aCTLA4/aPD1 combo data (Hutchins Freimark Brekken Huang etal) http://tinyurl.com/pchzr6h
Jan25-26 2016: “GTCbio's Novel Immunotherapeutics Summit”, San Diego
https://www.gtcbio.com/conferences/immunotherapeutics-summit-overview
GTC = Global Technology Community https://www.gtcbio.com/about-us
4 Sub-Conferences, including: 8TH IMMUNOTHERAPEUTICS & IMMUNOMONITORING
1-26-15: SESSION: ”Combinatorial Immunotherapies” - Moderator: Bruce Freimark, Peregrine Pharm.
4 Speakers:
*9:35am “DNA Vaccines with T-Cell Checkpoint Blockade”, Douglas McNeel, UNIV./WISCONSIN
*10:00am “Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Cells in the Tumor Microenvironment”, Bruce Freimark (Res.Dir./Preclin.Oncology), PEREGRINE PHARMACEUTICALS
Abstract: The underlying cause for the failure of immune checkpoint blockade is persistent, multifocal immune suppression in the tumor microenvironment. This is due to the absence of pre-existing antitumor Teff because of the action of immune checkpoints that induce immunosuppressive cytokines and recruit tumor infiltrating myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg), and M2 macrophages. Phosphatidylserine (PS) is segregated to the inner leaflet of the plasma membrane but becomes externalized to the outer leaflet in tumor cells where it contributes as an upstream checkpoint inhibitor to an immunosuppressive environment. Antibody blockade of PS reprograms the immune cells in the tumor microenvironment to support immune activation. Antibody-mediated PS blockade reduces the levels of MDSCs, TGF-beta, and IL-10 and increases the levels of TNF-alpha and IL-12. PS blockade also re-polarizes tumor-associated M2 macrophages to a M1 phenotype which promotes the maturation of dendritic cells and induces of adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of anti-CTLA-4 and anti-PD-1 antibodies in models of melanoma and breast cancer and correlates with an increase in the infiltration of activated T cells and the induction of adaptive immunity. In summary, PS blockade in combination with targeted therapy and other immune checkpoint inhibitors promotes a localized, anti-tumor response and represents a promising strategy to enhance cancer immunotherapy.
*10:25am “Cancer Vaccines in the Era of Checkpoint Blockade”, Willem Overwijk, MD.ANDERSON
*11:20am “Myeloid-Derived IL-10 & PD-1 Create a Vicious Immune...”, Keith Knutson, MAYO CLINIC
= = = = = = = = = = =OTHER KNOWN UPCOMINGS (2016):
Jan26: “GTCbio's Novel Immunotherapeutics Summit”, San Diego http://tinyurl.com/z3dyful
...10am, Dr. Bruce Freimark(ResDir./Preclin.Oncology): “Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Cells in the Tumor Microenvironment”
Jan26-28/Avid/Booth20: CASSS' 20th Symposium on the Interface of Reg.&Anal. Sciences for Biotech Health Products, WashDC http://www.casss.org/?WCBP1600
Mar6-11: CHI’s 23rd Molecular Med TRI-CON 2016, SanFran http://www.triconference.com (Speaker: Dr. Jeff Hutchins, VP/Preclin.Res.)
~Mar10: FY'16Q3 (qe 1-31-16) Financials & Conf. Call http://ir.peregrineinc.com/events.cfm
Mar14-17/Avid/Booth712: IBC's BioProcess Intl. West, Oakland http://www.ibclifesciences.com/BPIWest/overview.xml
Mar15-17: Immune Checkpoint Inhibitors Conf., Boston http://immune-checkpoint.com (Peregrine is 1 of 4 Corp. Sponsors; Speaker: Dr. Jeff Hutchins, VP/Preclin.Res.)
Jun6-9/Avid/Booth5562: BIO Intl. Convention, SanFran http://convention.bio.org
= = = = = = = = = =PREVIOUS BAVI MOA PRESENTATIONS:
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (UTSW/DUKE's Herbert K. Lyerly) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
BAVI MOA 8-26-15: Jeff Hutchins(VP/PreClin-Res) ImVacS’15 Talk – 29pg. Slideshow http://tinyurl.com/qz64pzg
…“Expansion & Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides): http://tinyurl.com/ooxkhq7
BAVI MOA 2-9-15: PPHM/ResDir. Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides: http://tinyurl.com/q6cx4w6
BAVI MOA 12-12-14 San Antomio Breast Cancer Symposium, Dr. Bruce Freimark, Bavi+anti-PD-1 vs. Breast Cancer http://tinyurl.com/p5ng6vs
BAVI MOA 11-2014 SITC’14: 3 posters on preclin. Bavi+aCTLA4/aPD1 combo data (Hutchins Freimark Brekken Huang etal) http://tinyurl.com/pchzr6h
